Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 5/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | DPYD | Q12882 | 1/20 | 0.31 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608578 | 0.79 | DYRK1A (0.47) | DYRK1AIMPDH2IMPDH1CHEK1GSK3B | |
| SCHEMBL18130749 | 0.79 | DYRK1A (0.40) | DYRK1AIMPDH2IMPDH1CHEK1GSK3B | |
| SCHEMBL2302616 | 0.79 | DYRK1A (0.47) | DYRK1AIMPDH2IMPDH1CHEK1LRRK2 | |
| SCHEMBL27174881 | 0.79 | DYRK1A (0.41) | DYRK1AIMPDH2IMPDH1GSK3BLRRK2 | |
| SCHEMBL27174878 | 0.76 | DYRK1A (0.38) | DYRK1AIMPDH2IMPDH1LRRK2 | |
| SCHEMBL3068718 | 0.73 | GPR35 (0.46) | DYRK1ACHEK1 | |
| SCHEMBL31677513 | 0.73 | IDO1 (0.34) | IDO1TDO2 | |
| SCHEMBL3073820 | 0.71 | DYRK1A (0.66) | DYRK1AIMPDH2IMPDH1GSK3BLRRK2 | |
| Hydrochloric Acid SCHEMBL2766486 | 0.71 | IDO1 (0.33) | IDO1TDO2 | |
| SCHEMBL3062645 | 0.70 | HTR6 (0.55) | DYRK1ACHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-0673937-B1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | EISAI CO LTD (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-0673937-A1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | DYRK1A 4492/4885IMPDH2 4659/4885IMPDH1 4617/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | DYRK1A 4492/4885IMPDH2 4659/4885IMPDH1 4617/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | DYRK1A 4839/4885IMPDH2 4600/4885IMPDH1 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.